Health

Exploiting research at University of Pittsburgh and UPMC, Novasenta has been established with $20m in seed financing.

The series C1 round pushed the Sanofi and Alexandria Real Estate Equities-backed oral therapeutics developer’s total funding to about $200m.

Immunotherapy developer Elixiron has closed its series A1 round with capital from investors including Hong Tai Electric Industrial.

Osage University Partners is among the returning backers that have helped push Stanford-linked Dice Molecules’ total funding to around $200m.

TXOne Nertworks has added $12.9m to its coffers, while C3 has pushed its series B round to $90m thanks to a $10m extension.

The oncology drug specialist has secured $100m from investors including existing shareholder Lilly Asia Ventures.

Over the past few years, roughly a fifth to a quarter of all corporate investors whose deals we track appear to be newcomers.

M12 backed three deals in recent days, including a $50m series D round for Split.io that also featured fellow corporates Atlassian and ServiceNow.

ThunderSoft-backed Shukun Technology has revealed fresh funding as it looks to develop its AI technology.

The Amgen-backed neurodegenerative disease treatment specialist is set to fund new medical studies.

Immunitas Therapeutics has reached $97m of total funding after announcing the close of its series B round featuring more than half a dozen corporates.